Press Releases - Boehringer Ingelheim
WEBFind the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Boehringer Ingelheim reports strong growth in 2023 and …
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Topline results from Boehringer's Phase III IPF ... - Boehringer Ingelheim
WEBSep 16, 2024 · Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function. 1 Based on these results, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food & Drug ...
First half of 2024: Boehringer Ingelheim progresses
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
Press Releases & Media Information | Boehringer Ingelheim US
WEBClick here to view all of Boehringer Ingelheim's latest press releases, with stories and breaking news on everything in the biopharmaceuticals industry.
Boehringer Ingelheim Faces Second Hung Jury in Chicago Zantac …
WEB6 days ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in ...
Boehringer Ingelheim GmbH - The New York Times
WEBHikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. By Chad Bray.
Boehringer Ingelheim expands immuno-oncology portfolio with …
WEBNov 22, 2023 · Boehringer Ingelheim is adopting a comprehensive approach to cancer therapy development including both cancer cell-directed and immuno-oncology approaches. This strategy aims to enable...
Boehringer Ingelheim produces its own green energy - Yahoo Finance
WEBJul 8, 2024 · With the new power plant, Boehringer Ingelheim is optimizing its energy supply and protecting the environment at the same time: Around 50,000 tons of CO 2 are saved per year. The CO 2 emissions...
Boehringer Ingelheim shares positive results from the first study ...
WEBMay 6, 2024 · Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular...